Genmab As Stock Price on November 27, 2024
| GMAB Stock | USD 21.50 0.34 1.61% |
Below is the normalized historical share price chart for Genmab AS extending back to June 01, 2009. This chart has been adjusted for all splits and dividends and is plotted against all major global economic recessions. As of today, the current price of Genmab AS stands at 21.50, as last reported on the 30th of November, with the highest price reaching 21.67 and the lowest price hitting 21.46 during the day.
If you're considering investing in Genmab Stock, it is important to understand the factors that can impact its price. Genmab AS holds Efficiency (Sharpe) Ratio of -0.26, which attests that the entity had a -0.26% return per unit of risk over the last 3 months. Genmab AS exposes twenty-three different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please check out Genmab AS's Risk Adjusted Performance of (0.20), market risk adjusted performance of (4.05), and Standard Deviation of 1.49 to validate the risk estimate we provide.
At present, Genmab AS's Total Stockholder Equity is projected to increase significantly based on the last few years of reporting. The current year's Liabilities And Stockholders Equity is expected to grow to about 37.1 B, whereas Common Stock Total Equity is forecasted to decline to about 52.4 M. . At present, Genmab AS's Price Book Value Ratio is projected to slightly decrease based on the last few years of reporting. The current year's Price To Operating Cash Flows Ratio is expected to grow to 28.58, whereas Price To Sales Ratio is forecasted to decline to 8.12. Genmab Stock price history is provided at the adjusted basis, taking into account all of the recent filings.
IPO Date 1st of June 2009 | 200 Day MA 26.7786 | 50 Day MA 22.8252 | Beta 0.859 |
Genmab |
Sharpe Ratio = -0.2632
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | GMAB |
Estimated Market Risk
| 1.51 actual daily | 13 87% of assets are more volatile |
Expected Return
| -0.4 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.26 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Genmab AS is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Genmab AS by adding Genmab AS to a well-diversified portfolio.
Price Book 3.0208 | Enterprise Value Ebitda 11.4275 | Price Sales 0.6881 | Shares Float 62.8 M | Wall Street Target Price 36.5556 |
Genmab AS Main Headline on 27th of November 2024
Why Is Genmab AS Among the Worst Performing Healthcare Stock... by finance.yahoo.com
We recently compiled a list of the 10 Worst Performing Healthcare Stocks in 2024. In this article, we are going to take a look at where Genmab AS stands against the other healthcare stocks. The Evolving Landscape of Global Healthcare Spending and Innovation The healthcare industry remains a vital and resilient sector which is driven
Genmab AS Valuation on November 27, 2024
It is possible to determine the worth of Genmab AS on a given historical date. On November 27, 2024 Genmab was worth 20.86 at the beginning of the trading date compared to the closed value of 21.16. We use multiple weighted factors in our valuation methodologies to arrive at the intrinsic value of Genmab AS stock. Still, in general, we apply an absolute valuation method to find Genmab AS's value based on its fundamental and technical indicators available within our service. As compared to an absolute model, our relative valuation model uses a comparative analysis of Genmab AS where we calculate exposure to its market risk and evaluate relevant financial multiples and ratios against Genmab AS's related companies.
| Open | High | Low | Close | Volume | |
| 20.76 | 20.76 | 20.46 | 20.65 | 1,157,925 | |
11/27/2024 | 20.86 | 21.17 | 20.84 | 21.16 | 787,442 |
| 21.50 | 21.67 | 21.46 | 21.50 | 575,331 |
| Backtest Genmab AS | | | Genmab AS History | | | Genmab AS Valuation | Previous | Next |
Genmab AS Trading Date Momentum on November 27, 2024
| On November 29 2024 Genmab AS was traded for 21.50 at the closing time. The top price for the day was 21.67 and the lowest listed price was 21.46 . The trading volume for the day was 575.3 K. The trading history from November 29, 2024 was a factor to the next trading day price jump. The overall trading delta against the next closing price was 1.61% . The overall trading delta against the current closing price is 1.61% . |
Genmab AS Fundamentals Correlations and Trends
By evaluating Genmab AS's financials over time, investors can gain insight into future company performance. However, you can also analyze the published financial statements to find patterns among Genmab AS's main balance sheet or income statement drivers and many other relevant indicators that can statistically be found significantly correlated or uncorrelated. Genmab financial account trend analysis is a perfect complement when working with valuation or volatility modules.About Genmab AS Stock history
Genmab AS investors dedicate a lot of time and effort to gaining insight into how a market's past behavior relates to its future. Access to timely market data for Genmab is vital when making an investment decision, and regardless of whether you use fundamental or technical analysis, your return on investment in Genmab AS will depend on recognizing future opportunities and eliminating past mistakes. Historical data analysis is the study of market behavior over a given time. Recorded market-related data such as price, volatility, and volume can be quantified and studied over a defined period. Through a detailed examination of a market's past behavior, traders and investors can gain perspective on the inner workings of that market. The information obtained throughout analyzing Genmab AS stock prices may prove useful in developing a viable investing in Genmab AS
| Last Reported | Projected for Next Year | ||
| Common Stock Shares Outstanding | 65.9 M | 62.6 M | |
| Net Income Applicable To Common Shares | 6.4 B | 6.7 B |
Genmab AS Quarterly Net Working Capital |
|
Genmab AS Stock Technical Analysis
Genmab AS technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
Price Boundaries
Genmab AS Period Price Range
Low | November 30, 2024
| High |
0.00 | 0.00 |
Genmab AS cannot be verified against its exchange. Please verify the symbol is currently traded on NASDAQ Exchange. If you still believe the symbol you are trying to look up is valid, please let us know, and we will check it as soon as possible.
Genmab AS November 30, 2024 Market Strength
Market strength indicators help investors to evaluate how Genmab AS stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Genmab AS shares will generate the highest return on investment. By undertsting and applying Genmab AS stock market strength indicators, traders can identify Genmab AS entry and exit signals to maximize returns
Genmab AS Technical and Predictive Indicators
Predictive indicators are helping investors to find signals for Genmab AS's price direction in advance. Along with the technical and fundamental analysis of Genmab Stock historical price patterns, it is also worthwhile for investors to track various predictive indicators of Genmab to make sure they correctly time the market and exploit it's hidden potentials. Even though most predictive indicators are useful for the short-term horizon, it's virtually impossible to predict the unforeseen market. For traders with a short-term horizon, predictive indicators add value when properly applied. Long-term investors, however, may find many predictive indicators less useful.
| Risk Adjusted Performance | (0.20) | |||
| Jensen Alpha | (0.43) | |||
| Total Risk Alpha | (0.66) | |||
| Treynor Ratio | (4.06) |
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Complementary Tools for Genmab Stock analysis
When running Genmab AS's price analysis, check to measure Genmab AS's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Genmab AS is operating at the current time. Most of Genmab AS's value examination focuses on studying past and present price action to predict the probability of Genmab AS's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Genmab AS's price. Additionally, you may evaluate how the addition of Genmab AS to your portfolios can decrease your overall portfolio volatility.
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments |